The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies

Russo, Antonio; Incorvaia, Lorena; Capoluongo, Ettore; Tagliaferri, Pierosandro; Re, Marzia Del; Malapelle, Umberto; Chiari, Rita; Conté, Pierfranco; Danesi, Romano; Fassan, Matteo; Ferrara, Roberto; Genuardi, Maurizio; Ghiorzo, Paola; Gori, Stefania; Guadagni, Fiorella; Marchetti, Antonio; Marchetti, Paolo; Midiri, Massimo; Normanno, Nicola; Passiglia, Francesco; Pinto, Carmine; Silvestris, Nicola; Tallini, Giovanni; Vatrano, Simona; Vincenzi, Bruno; Cinieri, Saverio; Beretta, Giordano D.

doi:10.1016/j.critrevonc.2021.103567

Cited by 31 publications

(20 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The adequate patient selection is essential to address the patients in the appropriate therapeutic paths. 49 , 50 , 51 Incorporating BRCA testing in the routine management of patients is a key requirement to help medical or surgical decision making. All the professionals involved in the multidisciplinary preventive and therapeutic pathway should be specifically trained to optimize and implement BRCA testing in clinical practice.…”

Section: Discussionmentioning

confidence: 99%

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

et al. 2022

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

et al. 2022

Self Cite

View full text Add to dashboard Cite

“…Tumor mutational status is biologically and clinically important in many types of tumors [84] and has made GIST a paradigmatic model of oncogene addiction. GISTs are composed of many different genetic subtypes.…”

Section: Discussionmentioning

confidence: 99%

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Dimino

Brando

Algeri

et al. 2022

Cancers

Self Cite

View full text Add to dashboard Cite

Gastrointestinal Stromal Tumors (GISTs) represent a paradigmatic model of oncogene addiction. Despite the well-known impact of the mutational status on clinical outcomes, we need to expand our knowledge to other factors that influence behavior heterogeneity in GIST patients. A growing body of studies has revealed that the tumor microenvironment (TME), mostly populated by tumor-associated macrophages (TAMs) and lymphocytes (TILs), and stromal differentiation (SD) have a significant impact on prognosis and response to treatment. Interestingly, even though the current knowledge of the role of immune response in this setting is still limited, recent pre-clinical and clinical data have highlighted the relevance of the TME in GISTs, with possible implications for clinical practice in the near future. Moreover, the expression of immune checkpoints, such as PD-L1, PD-1, and CTLA-4, and their relationship to the clinical phenotype in GIST are emerging as potential prognostic biomarkers. Looking forward, these variables related to the underlying tumoral microenvironment in GIST, though limited to still-ongoing trials, might lead to the potential use of immunotherapy, alone or in combination with targeted therapy, in advanced TKI-refractory GISTs. This review aims to deepen understanding of the potential link between mutational status and the immune microenvironment in GIST.

show abstract

“…Patients affected by DDR alterations should be discussed by a molecular tumor board, in order to identify those eligible for targeted therapies together with those affected by hereditary syndromes [121].…”

Section: Hereditary Implicationsmentioning

confidence: 99%

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer

Catalano

Borea

Puglisi

et al. 2022

Cancers

View full text Add to dashboard Cite

Major advances have been made in CRC treatment in recent years, especially in molecularly driven therapies and immunotherapy. Despite this, a large number of advanced colorectal cancer patients do not benefit from these treatments and their prognosis remains poor. The landscape of DNA damage response (DDR) alterations is emerging as a novel target for treatment in different cancer types. PARP inhibitors have been approved for the treatment of ovarian, breast, pancreatic, and prostate cancers carrying deleterious BRCA1/2 pathogenic variants or homologous recombination repair (HRR) deficiency (HRD). Recent research reported on the emerging role of HRD in CRC and showed that alterations in these genes, either germline or somatic, are carried by up to 15–20% of CRCs. However, the role of HRD is still widely unknown, and few data about their clinical impact are available, especially in CRC patients. In this review, we report preclinical and clinical data currently available on DDR inhibitors in CRC. We also emphasize the predictive role of DDR mutations in response to platinum-based chemotherapy and the potential clinical role of DDR inhibitors. More preclinical and clinical trials are required to better understand the impact of DDR alterations in CRC patients and the therapeutic opportunities with novel DDR inhibitors.

show abstract

The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies

Cited by 31 publications

References 31 publications

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

Implementation of preventive and predictive BRCA testing in patients with breast, ovarian, pancreatic, and prostate cancer: a position paper of Italian Scientific Societies

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors

Targeting the DNA Damage Response Pathway as a Novel Therapeutic Strategy in Colorectal Cancer

Contact Info

Product

Resources

About